Bristol-Myers Squibb (BMY) has faced a tumultuous period, despite positive Q4 2024 earnings results showing impressive revenue growth. Despite beating earnings, and posting better-than-expected sales in Q4, they issued weak guidance and announced plans to conduct $2 billion in cost cuts by 2027 affecting their short-term outlook negatively. On the other hand, their drug innovations, especially for their first schizophrenia drug in 30 years, have been applauded by market analysts like Jim Cramer who called the performance in this context a 'knocking it out of the park'. Despite the perceived positives and the commitment to research, the market has not reacted optimally to Bristol Myers Squibb's various strategies, emphasizing concerns about their long term prospects. The robust response from the investment community saw major holdings shift, with ample buys and sell-offs. On the other hand, their safe and steady dividends continue to appeal to many long-term investors.
Bristol-Myers Squibb BMY News Analytics from Fri, 06 Sep 2024 07:00:00 GMT to Sat, 08 Feb 2025 23:58:15 GMT -
Rating 0
- Innovation 5
- Information 7
- Rumor -1
